The Expert On IP For Internet Protocol: Interview With Scott Bradner 19/08/2016 by Intellectual Property Watch 1 Comment Fluent in both types of IP: Scott Bradner has been an architect of intellectual property (IP) policy for internet protocol (IP) standards. He played a core role in the development of internet protocol, leading to the very digital revolution we know today, as well as the next generation IPv6, all the while designing intellectual property policy to go along with it. Here is an interview with Bradner.
The Downfall Of Invention: A Broken Patent System 18/08/2016 by Intellectual Property Watch 1 Comment The cost of dozens of brand-name drugs have nearly doubled in just the past five years. Public outrage over drug prices extends from Capitol Hill to the presidential candidates to patients. In response, pharmaceutical executives are spending more on lobbying and marketing. Yet for all this attention, most of the proposed solutions for reducing prescription drug costs—tougher negotiations, appeals for transparent R&D costs or investigations into insurers—miss one of the primary sources of the problem: the way we award patents, writes Tahir Amin.
Number Of Unique Patent Assertions Declined Over Years, Patexia Finds 17/08/2016 by Intellectual Property Watch 3 Comments Pedram Sameni of Patexia writes: We recently studied the PTAB data and suggested that although the rise and fall in litigation indirectly affected the rise and fall in IPR challenges, the true driver of IPR challenges is the number of unique patents asserted each year. To learn more, we decided to look at the number of unique patents asserted against different defendants since 2010. We made several interesting discoveries, including the surprising fact that even though the number of cases has been rising, the number of unique patents asserted each year has been declining.
Focus On Medicines Patents & Prices Alone May Do More Harm Than Good 12/07/2016 by Intellectual Property Watch Leave a Comment Populism is in vogue these days and critics of pharmaceutical patents are trying to ride the wave, claiming that undermining patents will dramatically decrease prices but not reduce innovation. Both sides of that claim are flawed, writes Steven Tepp.
The Dutch & Pharma Policy: A Groundbreaking Presidency 05/07/2016 by Intellectual Property Watch 1 Comment The Netherlands’ Presidency of the European Council proved to be far from quiet in relation to pharmaceutical affairs. June 17 was the concluding Health Ministers Council (EPSCO) that signed off the most strongly-worded conclusions Brussels observers can recall. The meeting signaled the end of an overall successful and impactful Presidency in the highly sensitive field of medicines. The past semester has been eventful to say the least.
LinkedIn’s Patent Portfolio; Looking For Hidden Gems 23/06/2016 by Intellectual Property Watch 2 Comments John Sullivan writes: It’s obvious that this acquisition isn’t necessarily about the IP assets of LinkedIn. However, let’s have a closer look at LinkedIn’s portfolio to see if there are any hidden gems inside that would represent a nice fringe benefit to what already looks like a mutually beneficial acquisition.
Q&A With Erich Spangenberg On Patents And Drug Prices 03/06/2016 by Intellectual Property Watch 1 Comment Prices for drugs have long been a problem for developing countries but now have become out of reach for many in developed countries, sparking policy debates and efforts to address it. One of the top figures in the patent monetization business, industry maverick Erich Spangenberg offers a lively opinion on the underlying problem and how to fix it. To start? Stop granting patent extensions for minor changes.
Interview – Indigenous Concern Over Rising Focus On IP In WIPO TK Talks 02/06/2016 by Intellectual Property Watch 1 Comment Indigenous peoples have been the victims of repeated acts of biopiracy while the international community has failed to act to prevent it, indigenous representatives said in an interview this week. The World Intellectual Property Organization has been discussing ways to address that issue for some 16 years, without success. As negotiators continue to seek consensus on what a potential treaty could achieve, indigenous peoples feel the spotlight has drifted from their issues to technical issues of the intellectual property system and highlighted attention on users of the system.
Guilty As Charged? Pakistan And The Special 301 Reports 23/05/2016 by Intellectual Property Watch Leave a Comment Owais Hassan Shaikh writes: According to the section of US law on Special 301 reports, a country may be considered a priority foreign country even when it is fully compliant with the WTO Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS), the main multilateral agreement on IP rights today. Hence, this legislation and the determinations made in the Special 301 reports prioritize protection of commercial interests of the US nationals.
Can Patents Ever Be “Ever-Greened”? The Answer…They Are “Never-Greened” 20/05/2016 by Intellectual Property Watch 9 Comments “Ever-Greening of Patents” has been an expression that has been extensively used in debates related to the global pharmaceutical industry at least since the last two decades. Interestingly, this term has never been statutorily defined and hence has been applied most freely by professionals, policy makers and politicians alike. It would be appropriate to objectively examine whether patents in any jurisdiction can ever be “ever-greened”. A fitting initiation to this debate is the very concept of what a patent is from the very first principles, writes Prabuddha Ganguli.